Niels Behrendt

Dr. Niels Behrendt


Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2013 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
DMDaniel Hargbøl Madsen
Daniel Hargbøl Madsen
DLDaniel Leonard
Daniel Leonard
AMAndrius Masedunskas
Andrius Masedunskas
AMAmanda Moyer
Amanda Moyer
HJHenrik Jessen Jürgensen
Henrik Jessen Jürgensen
TBThomas Bugge
Thomas Bugge
Tissue remodeling processes critically depend on the timely removal and remodeling of preexisting collagen scaffolds. Nevertheless, many aspects related to the turnover of this abundant extracellular matrix component in vivo are still incompletely understood. We therefore took advantage of recent advances in optical imaging to develop an assay to visualize collagen turnover in situ and identify cell types and molecules involved in this process. Collagen introduced into the dermis of mice underwent cellular endocytosis in a partially matrix metalloproteinase–dependent manner and was subsequently routed to lysosomes for complete degradation. Collagen uptake was predominantly executed by a quantitatively minor population of M2-like macrophages, whereas more abundant Col1a1-expressing fibroblasts and Cx3cr1-expressing macrophages internalized collagen at lower levels. Genetic ablation of the collagen receptors mannose receptor (Mrc1) and urokinase plasminogen activator receptor–associated protein (Endo180 and Mrc2) impaired this intracellular collagen degradation pathway. This study demonstrates the importance of receptor-mediated cellular uptake to collagen turnover in vivo and identifies a key role of M2-like macrophages in this process.

23 May 2002 in Oncogene
Verified
Journal Article
Closed access
KLKarin List
Karin List
CHChristian C Haudenschild
Christian C Haudenschild
RSRoman Szabo
Roman Szabo
WCWanJun Chen
WanJun Chen
SWSharon M Wahl
Sharon M Wahl
TBThomas Bugge
Thomas Bugge

1 May 1989 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
RSR W Stephens
R W Stephens
JPJ Pöllänen
J Pöllänen
HTH Tapiovaara
H Tapiovaara
KLK C Leung
K C Leung
PSP S Sim
P S Sim
AVA Vaheri
A Vaheri
Human HT-1080 fibrosarcoma cells produce urokinase-type plasminogen activator (u-PA) and type 1 plasminogen activator inhibitor (PAI-1). We found that after incubation of monolayer cultures with purified native human plasminogen in serum-containing medium, bound plasmin activity could be eluted from the cells with tranexamic acid, an analogue of lysine. The bound plasmin was the result of plasminogen activation on the cell surface; plasmin activity was not taken up onto cells after deliberate addition of plasmin to the serum-containing medium. The cell surface plasmin formation was inhibited by an anticatalytic monoclonal antibody to u-PA, indicating that this enzyme was responsible for the activation. Preincubation of the cells with diisopropyl fluorophosphate-inhibited u-PA led to a decrease in surface-bound plasmin, indicating that a large part, if not all, of the cell surface plasminogen activation was catalyzed by surface-bound u-PA. In the absence of plasminogen, most of the cell surface u-PA was present in its single-chain proenzyme form, while addition of plasminogen led to formation of cell-bound two-chain u-PA. The latter reaction was catalyzed by cell-bound plasmin. Cell-bound u-PA was accessible to inhibition by endogenous PAI-1 and by added PAI-2, while the cell-bound plasmin was inaccessible to serum inhibitors, but accessible to added aprotinin and an anticatalytic monoclonal antibody. A model for cell surface plasminogen activation is proposed in which plasminogen binding to cells from serum medium is followed by plasminogen activation by trace amounts of bound active u-PA, to form bound plasmin, which in turn serves to produce more active u-PA from bound pro-u-PA. This exponential process is subject to regulation by endogenous PAI-1 and limited to the pericellular space.

31 March 2003 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
LELars H. Engelholm
Lars H. Engelholm
KLKarin List
Karin List
SNSarah Netzel-Arnett
Sarah Netzel-Arnett
ECEdna Cukierman
Edna Cukierman
DMDavid J. Mitola
David J. Mitola
TBThomas Bugge
Thomas Bugge
The uptake and lysosomal degradation of collagen by fibroblasts constitute a major pathway in the turnover of connective tissue. However, the molecular mechanisms governing this pathway are poorly understood. Here, we show that the urokinase plasminogen activator receptor–associated protein (uPARAP)/Endo180, a novel mesenchymally expressed member of the macrophage mannose receptor family of endocytic receptors, is a key player in this process. Fibroblasts from mice with a targeted deletion in the uPARAP/Endo180 gene displayed a near to complete abrogation of collagen endocytosis. Furthermore, these cells had diminished initial adhesion to a range of different collagens, as well as impaired migration on fibrillar collagen. These studies identify a central function of uPARAP/Endo180 in cellular collagen interactions.


1 December 2017 in Cell Reports
Verified
Journal Article
Open access
DMDaniel Hargbøl Madsen
Daniel Hargbøl Madsen
HJHenrik Jessen Jürgensen
Henrik Jessen Jürgensen
MSMajken Storm Siersbæk
Majken Storm Siersbæk
DKDorota Ewa Kuczek
Dorota Ewa Kuczek
LCLoretta Grey Cloud
Loretta Grey Cloud
TBThomas Bugge
Thomas Bugge
Physiologic turnover of interstitial collagen is mediated by a sequential pathway in which collagen is fragmented by pericellular collagenases, endocytosed by collagen receptors, and routed to lysosomes for degradation by cathepsins. Here, we use intravital microscopy to investigate if malignant tumors, which are characterized by high rates of extracellular matrix turnover, utilize a similar collagen degradation pathway. Tumors of epithelial, mesenchymal, or neural crest origin all display vigorous endocytic collagen degradation. The cells engaged in this process are identified as tumor-associated macrophage (TAM)-like cells that degrade collagen in a mannose receptor-dependent manner. Accordingly, mannose-receptor-deficient mice display increased intratumoral collagen. Whole-transcriptome profiling uncovers a distinct extracellular matrix-catabolic signature of these collagen-degrading TAMs. Lineage-ablation studies reveal that collagen-degrading TAMs originate from circulating CCR2+ monocytes. This study identifies a function of TAMs in altering the tumor microenvironment through endocytic collagen turnover and establishes macrophages as centrally engaged in tumor-associated collagen degradation.